We are live on ! Find out more
BOLT icon

Bolt Biotherapeutics
BOLT

29 hedge funds and large institutions have $7.33M invested in Bolt Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

0.05% less ownership

Funds ownership: 2.44% → 2.39% (-0.05%)

22% less funds holding

Funds holding: 37 → 29 (-8)

27% less capital invested

Capital invested by funds: $9.99M → $7.33M (-$2.66M)

80% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 10

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
29
Holders Change
-8
Holders Change %
-21.62%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
7
Reduced
4
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$49.2K
2
UBS Group
UBS Group
Switzerland
+$21.8K
3
Squarepoint
Squarepoint
New York
+$16.8K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$16.5K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$10.4K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$58.2K
2
Citadel Advisors
Citadel Advisors
Florida
-$42.3K
3
EGM
Engineers Gate Manager
New York
-$38.7K
4
BCM
Bridgeway Capital Management
Texas
-$32.2K
5
Goldman Sachs
Goldman Sachs
New York
-$26.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
1
Tang Capital Management
California
$1.53M – – –
VC
2
Vivo Capital
California
$1.41M – – –
SI
3
Sofinnova Investments
California
$1.1M – – –
PBPIA
4
Pivotal bioVenture Partners Investment Advisor
California
$757K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$468K +$49.2K +5,115 +10%
NFGH
6
Nan Fung Group Holdings
Hong Kong
$467K – – –
SB
7
Samsara BioCapital
California
$420K – – –
BOTOTLSJU
8
Board of Trustees of The Leland Stanford Junior University
California
$288K – – –
P
9
Pfizer
New York
$250K – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$150K +$16.5K +1,722 +10%
Renaissance Technologies
11
Renaissance Technologies
New York
$126K +$5.81K +605 +4%
BlackRock
12
BlackRock
New York
$107K -$702 -73 -0.5%
ACM
13
ADAR1 Capital Management
Texas
$98K – – –
UBS Group
14
UBS Group
Switzerland
$44.6K +$21.8K +2,269 +69%
Squarepoint
15
Squarepoint
New York
$33.6K +$16.8K +1,746 +71%
State Street
16
State Street
Massachusetts
$19K – – –
Northern Trust
17
Northern Trust
Illinois
$16.4K – – –
Mariner
18
Mariner
Kansas
$16K +$2.4K +250 +14%
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$8.69K +$10.4K +1,087 New
SG
20
StoneX Group
New York
$6.21K +$7.47K +777 New
XT
21
XTX Topco
Cayman Islands
$6.16K -$14.2K -1,475 -66%
Morgan Stanley
22
Morgan Stanley
New York
$4.65K – – –
TRCT
23
Tower Research Capital (TRC)
New York
$3.48K +$2.25K +234 +117%
Fidelity Investments
24
Fidelity Investments
Massachusetts
$3.24K -$58.2K -6,058 -94%
Bank of America
25
Bank of America
North Carolina
$2.25K – – –
1
2

BOLT Hedge Fund Activity: Q1 2025 in Review

29 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q1 2025, worth a combined $7.33M — down 27% from $9.99M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of BOLT and 2 opened new positions — a net loss of 8 holders — while 4 trimmed existing stakes and 7 added.

The largest buyer was Vanguard Group, adding an estimated $49.2K. The largest seller was Fidelity Investments, cutting an estimated $58.2K.

  • 29 institutional investors held Bolt Biotherapeutics (BOLT) as of Q1 2025, down from 37 in Q4 2024.
  • Funds reported $7.33M of Bolt Biotherapeutics stock for Q1 2025, down 27% quarter-over-quarter.
  • 2 funds opened new Bolt Biotherapeutics positions in Q1 2025 and 10 closed out, a net change of -8 holders.
  • The largest Bolt Biotherapeutics buyer in Q1 2025 was Vanguard Group, an estimated $49.2K added.
  • The largest Bolt Biotherapeutics seller in Q1 2025 was Fidelity Investments, an estimated $58.2K sold.

Based on aggregated 13F filings for Q1 2025.